Solace Therapeutics

About Solace Therapeutics

Solace Therapeutics was a medical technology company that focused on developing treatments for female Stress Urinary Incontinence (SUI). Founded in 2002, the company aimed to provide a non-surgical, office-based alternative for a condition affecting an estimated 15 million adult women in the U.S. alone.

The company's core product was the Vesair Bladder Control System, a small, polyurethane balloon inserted into the bladder in an office procedure without requiring anesthesia. Once inside, the balloon was filled with air and designed to float at the top of the bladder, acting as a "shock absorber" to reduce the sudden pressure changes that cause involuntary leakage during activities like coughing, laughing, or exercising. This approach differentiated it from other treatments that focus on strengthening the urethral closure force. The system was also reversible, with the balloon being easily deflated and removed in a similar in-office procedure.

Throughout its operation, Solace Therapeutics engaged in multiple clinical trials, such as the SUCCESS and VESAIR studies, to evaluate the safety and efficacy of its Vesair system, and it secured a CE mark for distribution in the European Union. The company raised a total of $51.4 million over six funding rounds from investors including New Enterprise Associates, Saints Capital, and S3 Ventures. Its last reported funding was a Series D round in February 2021. According to market analysis, the company is now considered to be out of business.